Business
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress
NEWTON, Mass., May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that initial data from a Phase 1 portion of the Ph 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis has been selected for a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress taking place June 9-12, 2022, in Vienna, Austria. The data are also being presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 4th.\n\"We are pleased to be sharing initial selinexor data in treatment-naïve patients with myelofibrosis at both EHA and ASCO,\" said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. \"JAK inhibitors remain the only class of approved therapies for myelofibrosis and there is a critical need for novel class of treatments that improve the hallmarks of this devastating blood disease including reductions in spleen size, as well as improvements in constitutional symptoms, quality of life, and anemia response. We look forward to sharing our findings and further exploring selinexor in this patient population.\"\nAdditional updated data will be presented during poster sessions at both EHA and ASCO.\nDetails for the EHA 2022 Hybrid Congress presentation are as follows:Poster Presentation\nTitle: A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosisSession type: Poster presentationPresenter: Haris Ali, City of HopeAbstract #: P1005Date and time: Friday, June 10, 2022; 16:30 - 17:45 CEST\nAbout XPOVIO® (selinexor)XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with Velcade® (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) i...